Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:AKRONASDAQ:PSTXNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.30+1.5%$17.47$13.40▼$25.23$3.73B0.651.94 million shs1.45 million shsAKROAkero Therapeutics$54.71+0.8%$42.56$21.02▼$58.40$4.36B-0.16994,920 shs2.27 million shsPSTXPoseida Therapeutics$9.50$9.48$2.32▼$9.67$928.85M1.63983,492 shsN/ARNAAvidity Biosciences$32.66-9.9%$29.49$21.51▼$56.00$3.94B0.951.46 million shs4.83 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.46%+3.87%+27.87%+29.73%+49.76%AKROAkero Therapeutics+0.79%+7.85%+37.29%+24.85%+137.66%PSTXPoseida Therapeutics0.00%0.00%0.00%0.00%+253.16%RNAAvidity Biosciences-9.88%-1.54%+17.19%+10.41%+22.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.4357 of 5 stars3.32.00.00.03.24.21.3AKROAkero Therapeutics4.0259 of 5 stars3.53.00.04.73.20.80.0PSTXPoseida Therapeutics0.4854 of 5 stars1.00.00.04.60.00.80.0RNAAvidity Biosciences2.42 of 5 stars4.50.00.00.03.90.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.69Moderate Buy$26.7920.12% UpsideAKROAkero Therapeutics 3.00Buy$82.5050.80% UpsidePSTXPoseida Therapeutics 2.00Hold$9.50N/ARNAAvidity Biosciences 3.00Buy$67.62107.03% UpsideCurrent Analyst Ratings BreakdownLatest PSTX, AKRO, RNA, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.006/9/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $75.006/6/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.006/5/2025ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/5/2025ACADACADIA PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Hold$18.00 ➝ $23.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/21/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.00 ➝ $35.005/20/2025ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $24.005/19/2025ACADACADIA PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $31.005/19/2025ACADACADIA PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/19/2025ACADACADIA PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.00 ➝ $26.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$996.28M3.75N/AN/A$2.63 per share8.48AKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/APSTXPoseida Therapeutics$150.86M6.16N/AN/A$1.08 per share8.80RNAAvidity Biosciences$8.93M440.93N/AN/A$6.76 per share4.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M$1.3728.5929.34N/A13.83%25.83%14.71%8/5/2025 (Estimated)AKROAkero Therapeutics-$151.76M-$1.95N/AN/AN/AN/A-32.46%-29.83%8/8/2025 (Estimated)PSTXPoseida Therapeutics-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/ARNAAvidity Biosciences-$212.22M-$3.00N/AN/AN/A-2,772.45%-27.66%-24.56%8/8/2025 (Estimated)Latest PSTX, AKRO, RNA, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/APSTXPoseida TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.292.11AKROAkero Therapeutics0.0517.2517.25PSTXPoseida Therapeutics0.683.203.20RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%AKROAkero TherapeuticsN/APSTXPoseida Therapeutics46.87%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%AKROAkero Therapeutics7.07%PSTXPoseida Therapeutics2.90%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million119.30 millionOptionableAKROAkero Therapeutics3079.72 million64.26 millionOptionablePSTXPoseida Therapeutics26097.77 million94.94 millionOptionableRNAAvidity Biosciences190120.52 million114.92 millionOptionablePSTX, AKRO, RNA, and ACAD HeadlinesRecent News About These CompaniesAvidity’s siRNA Muscular Dystrophy Drug Improves Mobility, Boosts Muscle StrengthJune 9 at 3:07 PM | biospace.comAvidity, FDA reach agreement on accelerated filing of rare disease drugJune 9 at 3:07 PM | statnews.comAvidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease TrialJune 9 at 3:07 PM | finance.yahoo.comAvidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Bank of America Analyst SaysJune 9 at 2:47 PM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Up Following Analyst UpgradeJune 9 at 12:46 PM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Price Target Raised to $75.00June 9 at 11:17 AM | marketbeat.comAvidity Bioscience updates on del-brax developmentJune 9 at 10:05 AM | thepharmaletter.comAvidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD ParticipantsJune 9 at 7:01 AM | prnewswire.comAvidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHDJune 9 at 7:00 AM | prnewswire.comCalifornia State Teachers Retirement System Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 7 at 3:55 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Hennion & Walsh Asset Management Inc.June 6, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $190,820.00 in StockJune 5, 2025 | marketbeat.comTwo Sigma Advisers LP Trims Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 5, 2025 | marketbeat.comStock Traders Buy Large Volume of Avidity Biosciences Put Options (NASDAQ:RNA)June 5, 2025 | americanbankingnews.comAvidity Biosciences Target of Unusually Large Options Trading (NASDAQ:RNA)June 4, 2025 | marketbeat.comAnalysts Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $66.38June 4, 2025 | americanbankingnews.comAmeriprise Financial Inc. Has $798,000 Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 3, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)June 2, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 1, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from BrokeragesJune 1, 2025 | marketbeat.comNuveen Asset Management LLC Sells 706,062 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)May 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsPSTX, AKRO, RNA, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$22.30 +0.32 (+1.46%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$22.16 -0.14 (-0.63%) As of 06/9/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Akero Therapeutics NASDAQ:AKRO$54.71 +0.43 (+0.79%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$54.77 +0.06 (+0.12%) As of 06/9/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Poseida Therapeutics NASDAQ:PSTXPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Avidity Biosciences NASDAQ:RNA$32.66 -3.58 (-9.88%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$32.76 +0.10 (+0.29%) As of 06/9/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
